Generex Biotech Immunotherapeutics Subsidiary to Present at the 41st Annual Meeting of The European Assoc for the Study of Diabetes
9th Sep 2005, 15:11 GMT
Generex Biotech Corp announced that Antigen Express its wholly owned immunotherapeutics subsidiary, will make the following presentations at the 41st Annual Meeting of the European Assoc for the Study of Diabetes held in Athens, Greece from 9/10/2005 - 15, 2005: * Study of T Cell Responses to Ii-Key/MHC Class II Epitope Hybrid Peptides in Human Type 1 Diabetes, a study -authored by H Beyan, RE Humphreys, and RDG Leslie * A Novel Approach to Study T Cell Response to Ii-Key/MHC Class II Epitope Hypbrid Peptides in Type 1 Diabetes, a study -authored by M Vadacca, GM Valorani, L Valente, RE Humphreys, and P Pozzilli The aims of the EASD are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and the facilitation of its application.
Latest news from Bio-Technology News from myHealthcareNews.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress